



Colc

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

<b>REQUEST FOR CERTIFICATE OF CORRECTION PURSUANT TO 37 C.F.R. § 1.322, 1.323</b>		Docket Number: <b>1662/63102</b>	Conf. No.: <b>8876</b>
Application Number <b>10/785,244</b>	Filing Date <b>February 23, 2004</b>	Examiner <b>Brenda Libby Coleman</b>	Art Unit <b>1624</b>
Patent Number <b>7,071,331</b>	Issue Date <b>July 4, 2006</b>		
Invention Title <b>SYNTHESIS OF QUETIAPINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF</b>		Inventor(s) <b>Dov DILLER et al.</b>	

Address to:

Commissioner For Patents  
Office of Patent Publication  
Attn: Certificate of Correction Branch  
P. O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to : Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Date: **May 27, 2009**

Signature: **Georgia Galanis**

Sir:

Patentee requests that the enclosed Certificate of Correction be issued for the above Patent under authority of 35 U.S.C. §§ 254, 255. The exact column and line number where the errors occur in the patent are listed on the enclosed certificate.

The errors that appear in this patent due to Applicants' mistake are clerical, typographical or of a minor character and occurred in good faith, and the correction does not involve a change in the patent so as to represent new matter or to require reexamination.

The other errors in this patent are Patent Office errors.

The Commissioner is authorized to charge payment of the 37 C.F.R. § 1.20(a) certificate of correction fee of \$100.00 to the deposit account of Kenyon & Kenyon LLP, deposit account No. 11-0600. The Commissioner is also authorized to charge any additional fees or credit any overpayment in connection with this paper to Deposit Account No. 11-0600.

Dated: **May 26, 09**

By: **Payam Moradian**

Payam Moradian, Reg. No. 52,048

**Certificate**

**JUN 05 2009**

**of Correction**

06/04/2009 SSESHE1 00000005 7071331

01 FC:1811 100.00 DA

KENYON & KENYON LLP

One Broadway

New York, New York 10004

(212) 425-7200 (telephone)

(212) 425-5288 (facsimile) 00000005 110600 7071331

01 FC:1811

100.00 DA

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

**PATENT No.** : 7,071,331

**Page 1 of 2**

**APPLICATION NO.:** 10/785,244

**DATED** : February 23, 2004

**INVENTOR(S)** : Dov DILLER et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 1, lines 18-19, change "2-(2-(4-dibenzo[b,f]-[1,4]thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol" to -- 2-(2-(4-dibenzo[b,f]-[1,4]thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol --

Column 2, lines 7-8, change "...tetrabutyammonium bromide..." to -- tetrabutylammonium bromide --

Column 2, line 14, change "...recrystallizion..." to -- recrystallization --

Column 2, lines 41-42, change "...the well-know dihydrochloride..." to -- the well-known dihydrochloride --

Column 2, line 55, change "...in the practice opf the present invention..." to -- in the practice of the present invention --

Column 4, line 8, change "...obtainable from quetiapine base by qutemarization..." to -- obtainable from quetiapine base by quaternization --

Column 4, line 49, change "The present invention is certain of its embodiments..." to -- The present invention in certain of its embodiments --

Column 5, line 7, change "The precipitae was collected..." to -- The precipitate was collected --

Column 6, line 64, change "11-piperazinyl dibenzo {b,f}[1,4] thiazepinehydrochloride" to -- 11-piperazinyl dibenzo[b,f][1,4] thiazepine hydrochloride --

**MAILING ADDRESS OF SENDER**

**Patent No. 7,071,331**

KENYON & KENYON LLP  
One Broadway  
New York, NY 10004

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

**PATENT No.** : 7,071,331

**Page 2 of 2**

**APPLICATION NO.:** 10/785,244

**DATED** : February 23, 2004

**INVENTOR(S)** : Dov DILLER et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 7, line 16, change "11-piperazinyl dibenzo{b,f}[1,4] thiazepinehydrochloride" to -- 11-piperazinyl dibenzo[b,f][1,4] thiazepine hydrochloride --

Column 9, line 9, change "...Recrystallization of Crude OTP Hemifumarate..." to -- Recrystallization of Crude QTP Hemifumarate --

Column 9, line 17, change "a-5,1,0,2-micron filer" to -- a-5,1,0.2-micron filter --

Column 9, line 62, change "11-piperazinyl dibenzo[b,f]-[1,4]thiazeine" to -- 11-piperazinyl dibenzo[b,f]-[1,4]thiazepine --

Column 10, lines 60-61, change "11-piperazinyl dibenzo[b,f]-[1,4]thiazapine" to -- 11-piperazinyl dibenzo[b,f]-[1,4]thiazepine --

**MAILING ADDRESS OF SENDER**

**Patent No. 7,071,331**

KENYON & KENYON LLP  
One Broadway  
New York, NY 10004